{
  "id": 11040644,
  "title": "Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.",
  "url": "https://urgent.news/2026/09/30/viking-therapeutics-stock-soars-36-on-weight-loss-drug-data-why-its",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T21:00:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/30/viking-therapeutics-stock-soars-20-on-weight-loss/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Viking Therapeutics stock surged by 36% after unveiling promising data from a weight-loss drug clinical trial, sparking questions about the company's potential. While Eli Lilly and Novo Nordisk maintain their leading positions in the weight loss drug market, Viking Therapeutics (NASDAQ: VKTX) is making noteworthy progress in clinical stages. Recently, the clinical-stage biotech experienced a significant rise in its stock price, jumping over 30% in a single day. To understand the implications of these results, it is essential to delve into the mechanism behind GLP-1-based weight loss medicines. These medications function by imitating naturally occurring hormones like GLP-1, which promote feelings of fullness. This leads patients to consume fewer calories, ultimately contributing to weight loss.",
  "summary": "There could be more catalysts for the biotech over the next 18 months.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.",
        "url": "https://urgent.news/2026/09/30/viking-therapeutics-stock-soars-36-on-weight-loss-drug-data-why-its-11041669",
        "published": "2026-09-30T21:20:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}